In connection with the execution of the merger agreement, certain stockholders of 2seventy bio owning approximately 5.3% of the outstanding shares of 2seventy bio’s common stock have entered into ...

Enrollment in MAD portion of the trial continues with higher doses being evaluated OXFORDSHIRE, UK & CONSHOHOCKEN, PA & GAITHERSBURG, MD, USA I March 10, 2025 I Immunocore Holdings plc (Nasdaq: IMCR) ...

COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise ...

EMERYVILLE, CA, USA I March 10, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

CHENGDU, China I March 10, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's ...

BOTHELL, WA, USA I March 10, 2025 I Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted ...

AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- ...